📰 Alpine Trial News

Alpine Trial News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Alpine Trial. Real-time updates on events, politics, business and more.

FDA Approves Label Updates to Include New Data for Axi-Cel in LBCL, Zanubrutinib in CLL

December 22, 2023

The FDA has approved label updates for zanubrutinib to include data from the ALPINE trial in relapsed/refractory chronic lymphocytic leukemia, and axicabtagene ciloleucel to include findings from the primary overall survival analysis of the ZUMA-7 trial in relapsed/refractory large B-cell lymphoma.

Mehrdad Mobasher Frank Neumann Clinical Development At Kite Clinical Development Label Updates For Zanubrutinib Alpine Trial

Source: onclive.com

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

December 20, 2023

Jennifer R. Brown, MD, PhD, presents data from the extended follow-up of the ALPINE study investigating zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

San Diego United States Jenniferr Brown Extended Follow Up Zanubrutinib Versus Ibrutinib Refractory Chronic Lymphocytic Leukemia

Source: onclive.com

Acalabrutinib and Zanubrutinib Produce Similar PFS in a Matching-Adjusted Indirect Comparison in R/R CLL

June 8, 2023

Acalabrutinib and zanubrutinib demonstrated similar investigator-assessed progression-free survival in patients with relapsed/refractory chronic lymphocytic leukemia.

Acalabrutinib Calquence Acalabrutinib And Zanubrutinib Patients With Relapsed Refractory Chronic Lymphocytic Leukemia Ascend Trial Alpine Trial

Source: onclive.com